Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Nutrition. 2020 May;73:110720. doi: 10.1016/j.nut.2020.110720. Epub 2020 Jan 7.
We report the case of a 62-y-old woman with short bowel syndrome (SBS) and chronic renal failure, successfully treated with teduglutide, who underwent comprehensive systematic nutritional assessment including bioelectrical impedance vectorial analysis (BIVA). The patient did not tolerate the attempt of gradual suspension of parenteral nutrition (PN), bumping into the worsening of nutritional status and renal function. She was declared eligible for teduglutide, a glucagonlike peptide 2 analog that stimulates structural and functional intestinal adaptation and increases nutrient and fluid absorption. To date, there is no standardized nutritional management protocol for PN-dependent SBS patients treated with teduglutide. We here report our first 1-y follow-up data. The patient underwent comprehensive systematic nutritional assessment initially every 2 wk, then monthly. It included handgrip strength (HGS), blood tests (particularly serum creatinine, estimated glomerular filtration rate, urea, electrolytes, micronutrients, serum albumin), fluid intake, urine output, quality-of-life (QoL) evaluation, and BIVA, which estimates fat-free mass (FFM) and measures phase angle (PhA) and hydration status. At treatment initiation, the patient was on PN 3 d/wk. After 3 mo, she was weaned off PN. At 1 y, weight and serum albumin were reduced (-7.5 kg and -0.6 g/dL, respectively); FFM, PhA, and HGS slightly decreased; hydration status and renal function were preserved; and QoL subtly improved. No relevant clinical complications or metabolic imbalances occurred. The inclusion of BIVA in the comprehensive systematic nutritional assessment of SBS patients treated with teduglutide could be proposed for appropriate and safe management, particularly in the presence of renal impairment.
我们报告了一例 62 岁患有短肠综合征(SBS)和慢性肾衰竭的女性患者,她成功接受了特杜格鲁肽治疗,在治疗过程中进行了全面系统的营养评估,包括生物电阻抗向量分析(BIVA)。该患者无法耐受逐渐停止肠外营养(PN)的尝试,导致营养状况和肾功能恶化。她被认为适合接受特杜格鲁肽治疗,这是一种胰高血糖素样肽 2 类似物,可刺激肠结构和功能的适应,增加营养和液体吸收。迄今为止,对于接受特杜格鲁肽治疗的依赖 PN 的 SBS 患者,尚无标准化的营养管理方案。我们在此报告首例 1 年随访数据。患者最初每 2 周进行一次全面系统的营养评估,然后每月进行一次。评估内容包括握力(HGS)、血液检查(特别是血清肌酐、估计肾小球滤过率、尿素、电解质、微量营养素、血清白蛋白)、液体摄入、尿液输出、生活质量(QoL)评估和 BIVA,BIVA 可估计去脂体重(FFM)并测量相位角(PhA)和水合状态。在开始治疗时,患者每周接受 3 天的 PN。3 个月后,她停止了 PN。在 1 年时,体重和血清白蛋白下降(分别为-7.5kg 和-0.6g/dL);FFM、PhA 和 HGS 略有下降;水合状态和肾功能保持不变;QoL 略有改善。没有发生相关的临床并发症或代谢失衡。对于接受特杜格鲁肽治疗的 SBS 患者,在全面系统的营养评估中纳入 BIVA 可能有助于进行适当和安全的管理,特别是在存在肾功能损害的情况下。